Stephen Henderson, MD
Family Medicine · New Hope, ALNPI 1366523110
Payments from drug & device makers
Across 235 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Lilly USA, LLC$494
- Pfizer$414
- Amgen$392
- Vanda Pharmaceuticals Inc.$220
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,587100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,454 |
| AstraZeneca | 20 | $1,194 |
| Lilly USA, LLC | 25 | $494 |
| Pfizer | 22 | $414 |
| Amgen | 11 | $392 |
| Vanda Pharmaceuticals Inc. | 10 | $220 |
| Boehringer Ingelheim | 6 | $205 |
| Inspire Medical Systems, Inc. | 3 | $193 |
| Johnson & Johnson | 6 | $180 |
| Sunovion Pharmaceuticals Inc. | 11 | $178 |
| Abbott | 9 | $175 |
| Novartis | 8 | $163 |
| Bayer | 3 | $158 |
| Genentech USA, Inc. | 2 | $157 |
| Biodelivery Sciences International, Inc. | 2 | $132 |
| Antares Pharma, Inc. | 1 | $113 |
| Novo Nordisk | 3 | $109 |
| GSK | 2 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Avanir Pharmaceuticals, Inc. | 4 | $72 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Vertex | 1 | $30 |
| Eisai Inc. | 2 | $29 |
| Boston Scientific | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Merck | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,614 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $100,362 |
| JardianceEmpagliflozin | 112 | $98,014 |
| MounjaroTirzepatide | 80 | $83,399 |
| OzempicSemaglutide | 72 | $75,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $47,334 |
| FarxigaDapagliflozin Propanediol | 45 | $43,220 |
| VraylarCariprazine Hcl | 25 | $35,136 |
| JanuviaSitagliptin Phosphate | 46 | $34,648 |
| TrulicityDulaglutide | 28 | $30,251 |
| LinzessLinaclotide | 36 | $30,174 |
| GemtesaVibegron | 40 | $25,323 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $21,837 |
| Repatha SureclickEvolocumab | 19 | $18,687 |
| RybelsusSemaglutide | 13 | $17,730 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 758 | $17,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $205 | $132,463153 claims |
| Lilly USA, LLCMounjaro, Trulicity | $494 | $113,649108 claims |
| PfizerEliquis, Premarin | $414 | $103,930174 claims |
| Novo NordiskOzempic, Rybelsus | $109 | $93,11585 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $108 | $89,247149 claims |
| AbbVieVraylar, Linzess | $1,454 | $65,31161 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,194 | $60,62086 claims |
| MerckJanuvia, Lagevrio (Eua) | $15 | $44,80958 claims |
| Johnson & JohnsonXarelto | $180 | $13,26314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in New Hope
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.